Materials and methods
Human tissue
Human participants with AD were selected from the Massachusetts Alzheimer’s Disease Research Center brain bank using the following criteria: (i) clinical diagnosis of dementia due to probable AD; (ii) postmortem confirmation of AD diagnosis; (iii) Braak stage V–VI determined by total tau immunostain and Bielchowsky’s silver stain of NFTs; (iv) minimal comorbidities; and (v) patients considered as “high seeders” according to our previously published paper [
17]. Human brain tissues were collected with informed consent of patients or their relatives and approval of local institutional review boards at Massachusetts General Hospital. Approximatively, 5 g of frozen frontal cortex corresponding to Brodmann area 8/9 and 7 (BA 8/9 and BA 7) from eight different AD cases (age-matched male and female donors) were dissected and kept at −80 °C until processing for either SARK or HMW tau extraction.
For each case, frozen human tissue (5 g/case) was thawed on wet ice, the meninges and white matter were removed and the gray matter processed according to previously described sarkosyl extraction protocols [
22,
42]. Gray matter was Dounce homogenized in 9 volumes per weight (
v/w) high salt buffer (10 mM Tris pH 7.4, 10% sucrose, 0.8 M NaCl, 1 mM EDTA, 0.1% sarkosyl and 1× protease/phosphatase inhibitor cocktail, #5872, Cell signaling) in a 15 ml glass homogenizer with 15 up and down strokes at 70% power by hand on ice. Homogenates were transferred to a 50 ml Falcon tube and centrifuged 10,000
g for 10 min at 4 °C. The supernatants were collected and filtered through a Kimwipe into a 50 ml Falcon tube. Homogenization and centrifugation/filtration steps were repeated once to increase the yield. A solution of 25% sarkosyl in distilled water was added to the total volumes of supernatant to get a final concentration of 1% sarkosyl and left incubating for 1 h under agitation at room temperature (RT). The supernatants were then ultracentrifuged at 300,000
g for 1 h at 4 °C, the myelin and supernatant carefully discarded and the pellets rinsed twice and resuspended in 1 ml PBS before ultracentrifugation at 250,000
g for 30 min at 4 °C. Pellets were resuspended and broken down into small pieces in 1 ml PBS and left overnight under agitation at RT. After a quick spin (1 min at 1000 g), pellets were broken up using a 27-gauge needle and sonicated with 20 short pulses at power 2 on ice using a handheld sonicator (QSonica). Samples were then centrifuged 30 min at 100,000
g at 4 °C, the supernatants discarded, the pellets resuspended in 200 µl PBS 1× and sonicated with 60 short pulses before centrifugation for 30 min at 10,000
g at 4 °C. The final supernatant contained the sarkosyl-insoluble tau species (SARK tau) and was stored at − 80 °C until further use. Depending on the experimental condition, SARK tau samples were extemporaneously sonicated for 60 short pulses on power 2 on ice using a handheld sonicator as recommended in the literature [
22,
42].
For each case, frozen human tissue (5 g/case) was dissected as described above, and the gray matter was Dounce homogenized in 5
v/
w buffer containing phosphate buffer saline (PBS) and 1X protease inhibitor (#5871, Cell signaling) in a 15 ml glass homogenizer with 30 up and down strokes at 70% power by hand on ice. The homogenates were transferred to a 50 ml Falcon tube and centrifuged at 10,000
g for 10 min at 4 °C. The supernatants were collected and kept at − 80 °C until further processing. The total volumes of soluble brain extracts were separated by SEC as previously described [
17] on a single Superdex200 10/300GL column (no. 17–5175-01, GE Healthcare) in PBS (no. P3813, Sigma-Aldrich, filtered through a 0.2-um membrane filter), at a flow rate of 0.5 ml/min using an AKTA purifier 10 (GE Healthcare). For each run, 5 ml of soluble brain extract was loaded onto the column and 28 fractions of 2.5 ml were collected. Fractions 2, 3 and 4 containing HMW tau (400–600 kDa) were pooled and centrifuged at 150,000
g for 30 min at 4 °C. Concentrated pellets were subsequently resuspended in PBS 1× and stored at − 80 °C until further use.
Tau immunodepletion
To verify the tau-specific effects of the SARK and HMW samples, we immunodepleted total tau using HT7 antibody (MN1000, Invitrogen). PureProteome Protein G Magnetic Beads (LSKMAGG02, Millipore Corp) were resuspended by vortexing and 25 µl of the suspended beads were used for each sample. Using a magnetic rack, the storage buffer was removed and discarded. Beads were washed three times with 50 µl PBS 1×, and then 50 µl of HT7 antibody was added. The bead-HT7 solution was incubated for 1 h at 4 °C with head-over-tail rotation. The antibody flow-through supernatant was removed using a magnetic rack, and the beads were washed two more times with PBS. Next, 75 µl of either SARK or HMW tau was incubated with antibody–bead complexes overnight at 4 °C with head-over-tail rotation. The next morning, tau-immunodepleted supernatant was collected using a magnetic rack and stored at − 80 °C until further use. Immunodepletion was repeated twice more on the collected supernatant to fully capture residual tau in the sample. Tau immunodepletion was confirmed by western blotting and tau seeding assay normalizing on total protein levels (Supplementary Fig. 4a-c).
Total tau quantification by western blot
Each SARK and HMW tau sample was run on a denaturing western blot (WB) to quantify total tau monomer equivalents. Samples were diluted in 1X NuPAGE LDS sample buffer (Thermo Fisher) and 1X NuPAGE sample reducing agent (Thermo Fisher), incubated for 5 min at 95 °C and loaded onto a NuPAGE 4–12% Tris/Bis gel (Thermo Fisher) with NuPAGE MOPS running buffer (Thermo Fisher). Proteins were transferred onto a nitrocellulose membrane using iBlot 2 gel transfer device (7 min at 25 V, Thermo Fisher). Membranes were incubated for 1 h at room temperature (RT) with agitation in Intercept blocking buffer (Licor), then incubated overnight at 4 °C with anti-total tau primary antibody solution (1: 5000, DAKO A0024). After 1 h incubation at RT in the corresponding secondary antibody solution (donkey anti-rabbit 800), membranes were revealed using Licor Odyssey Clx. Recombinant 2N4R human Tau (Tau441, AG960, Millipore) at serial dilutions ranging from 20 to 0 µg/ml total tau was used to generate a calibration curve and calculate total tau in our samples.
Total tau quantification by ELISA
Each SARK and HMW tau sample was also run on an MSD ELISA plate (Phospho(Thr231)/total tau kit, K151221D, Meso Scale Discovery) according to the manufacturer’s protocol. Comparing total tau quantifications by WB and ELISA gave insights into the amount of tau oligomers in each sample.
Proteinase K digestion
SARK and HMW tau seeds (2 µg total tau per condition) were incubated with 0–10 µg/ml proteinase K (AM246, Thermo Fisher) in 10 mM Tris–HCl, pH 7.4, for 10 min at RT as described previously [
37]. Digestion was stopped by denaturing samples 5 min at 95 °C as described above for WB. Digested samples were loaded onto a NuPAGE 4–12% Tris/Bis gel (Thermo Fisher) with NuPAGE MES running buffer (Thermo Fisher). Anti-total tau antibody (1: 5000, A0024, DAKO) was used as the primary antibody.
Negative staining electron microscopy
For electron microscopy (EM), 0.3 µg monomeric equivalent of total tau was loaded onto F/C 300-mesh nickel grids for 2 min before excess solution was removed. After a quick wash with ultrapure water, 3 µl of 2% uranyl acetate was applied to the grid and incubated for 90 s, the excess wicked away, and grids were air-dried before imaging. Images were taken on a Thermo Fisher Scientific T12 electron microscope at the Harvard Medical School Molecular Electron Microscopy Suite (HMS MEMS) at magnifications of 67,000× and 150,000×.
For quantification of fibril-like structures, a JEOL 1011 electron microscope was used to acquire 20 systematically randomly sampled grid squares at magnification 100,000× where the microscopist was blinded to sample identities. Fibrils were characterized and selected using PHF-resembling criteria: 10–20 nm in width and at least half a turn of the helical filament (> ~ 35 nm) in length. Quantification data were reproduced by two distinct experimenters on four different AD cases, with consistent results.
In vitro seeding assay
For in vitro seeding assay, we used the widely used FRET-biosensor assay [
17,
24] with cells stably expressing the PS19-mutant tau repeat domain conjugated to either cyan fluorescent protein (CFP) or yellow fluorescent protein (YFP) (TauRD-P301S-CFP/YFP). Briefly, cells were plated on 96-well plates (Costar, previously coated with 1:20 poly-
d-lysine) at a density of 40,000 cells per well and cultured for 24 h at 37 °C, 5% CO
2 in Dulbecco’s modified Eagle medium (DMEM), 10% fetal bovine serum (FBS) and 1% penicillin–streptomycin. SARK and HMW tau extracts (8 ng total tau per well) were incubated with 1% Lipofectamine 2000 transfection reagent (Thermo Fisher) in opti-MEM (Thermo Fisher, final volume of 50 µl per well) for 20 min at RT before being added to the cells. After 24 h, cells were collected for subsequent flow cytometer analysis of seeding, i.e., FRET signal. The medium was removed, 50 µl trypsin 1X was added to each well for 5 min at 37 °C, and the reaction was stopped by adding 150 µl fresh medium. Cells were transferred to 96-well U-bottom plates (Corning), pelleted at 1500 rpm for 10 min, resuspended in 2% paraformaldehyde (PFA) in PBS for 20 min at RT and pelleted again at 1500 rpm for 10 min. Cells were finally resuspended in 150 µl per well PBS and run and analyzed on the MACSQuant VYB (Miltenyi) flow cytometer as previously described [
17]. For each well, tau seeding value was calculated by multiplying the percentage of FRET-positive cells by the median fluorescence intensity of that FRET-positive population (integrated FRET density or IFD). Each sample was loaded in triplicate and three experiments were performed independently. Whether tau samples were sonicated or not is specified in the legend of each figure.
In vivo seeding in tau transgenic mice
Three-month-old male PS19 tau transgenic mice (B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J, Jackson Laboratory) overexpressing the human 1N4R isoform of tau with a P301S mutation were used. Following anesthesia with 1.5% (vol/vol) isoflurane, mice were fixed in a stereotaxic frame, ophthalmic ointment was placed on the eyes and lidocaine hydrochloride (2 mg/kg) was subcutaneously administered under the scalp skin before the beginning of surgery. Mice were intracerebrally injected into CA1 of the hippocampus (anteroposterior − 2.4 mm from bregma, mediolateral ± 1.5 mm from midline and dorsoventral − 1.6 mm from the skull surface) using a 33-gauge blunt-tip needle fixed to a Hamilton syringe. Each mouse was bilaterally injected with 1 µg non-sonicated SARK (n = 8: 3 with #1892, 5 with #2399) or HMW (n = 8: 3 with #1892, 5 with #2399) tau diluted in PBS (2.33 µl/site) at a flow rate of 0.2 µl/min. SARK and HMW samples immunodepleted for total tau (n = 2/group), as well as PBS alone (n = 7) were used as controls. After surgery, the skin was sutured and buprenorphine hydrochloride (0.05 mg/ml) was subcutaneously administered every 12 h for 72 h. Acetaminophen (300 mg/kg) was added to drinking water ad libitum for 72 h.
Three months after injection, mice were euthanized with CO2 and transcardially perfused with ice-cold PBS for 5 min at 20 ml/min. The brains were removed and the hemispheres separated. The left hemisphere was post-fixed for 24 h in 4% PFA and cryoprotected in 30% sucrose for 72 h before sectioning. 40 µm-thick coronal sections were sliced using a freezing microtome and were collected in series at 400 µm intervals.
Experiments were also performed in Tau22 mice, which express human tau with a double mutation G272V/P301S under a neuron-specific Thy1.2 promoter. Because of the more aggressive phenotype of this line, Tau22 mice of either sex were injected at 2 months of age, euthanized 2 months after injection and processed similarly to injected PS19 mice (n = 3/group). SARK samples were hand-sonicated for 60 pulses at power 2 prior to injection into Tau22 mice to assess the effect of sonication in vivo.
All animal care, housing and experiments were performed in compliance with the guidelines established by the Massachusetts General Hospital institutional animal care and use committee and in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Immunohistochemistry
Free-floating 40 µm-thick coronal sections were washed in 0.2% Triton X-100 PBS and incubated for 30 min in 0.3% hydrogen peroxide. After washing in 0.2% Triton X-100 PBS, sections were blocked in 4.5% normal goat serum (Vector Laboratories) in 0.2% Triton X-100 PBS for 1 h then incubated in primary antibody solution (Table S1) in blocking solution at 4 °C overnight. The next day, sections were washed in 0.2% Triton X-100 PBS and incubated in secondary antibody solution for 1 h before amplification of the signal by incubation in Vectastain ABC kit (1:400, Vector Laboratories) for 1 h. After washing in 0.2% Triton X-100 PBS, the sections were incubated for 1 min in 3,3´-diaminobenzidine (DAB, Vector Laboratories), then mounted on Superfrost Plus slides (Fisher Scientific), dehydrated in increasing concentrations of ethanol/xylene and coverslipped with Eukitt (Sigma-Aldrich).
Human formalin-fixed paraffin-embedded brain tissue sections from the contralateral hemisphere of AD cases #1892 and #2399 were stained for microglia (Iba1, abcam, 1:500) using DAB and counterstained with hematoxylin following the Leica autostainer protocol (Bond RX autostainer, Leica Biosystems). Slides were dehydrated and coverslipped with Permount mounting medium (Thermo Fisher).
Immunofluorescence
Free-floating 40 µm-thick coronal sections were washed in PBS, blocked with 4.5% normal goat serum in 0.2% Triton X-100 PBS for 1 h and then incubated in primary antibody solution at 4 °C overnight. The next day, sections were washed in PBS and incubated in secondary antibody solution for 1 h before being mounted on Superfrost Plus slides and coverslipped with DAPI-containing Fluoromount-G (0100-20, Southern Biotech).
Thioflavin-S staining
Free-floating 40 µm-thick coronal sections were washed in PBS, mounted on Superfrost Plus slides and let dry overnight. The following day, sections were quickly rinsed in PBS 1X before incubation in 0.05% Thioflavin-S (ThioS, T1892-25G, Sigma-Aldrich) in 50% ethanol for 8 min in the dark. Sections were then briefly rinsed in 80% ethanol and transferred to dH2O for 5 min prior to coverslipping.
Image analysis
Immunohistology images were acquired at 20 × using a NanoZoomer (Hamamatsu). Manual segmentation of the different brain regions and thresholding of each channel were then performed on three sections adjacent to the injection site using QuPath software. Staining-positive cells were manually counted using QuPath cell counter plug-in. Quantification in the perirhinal/entorhinal cortex was performed on six sections spanning the dorsal and ventral hippocampus. All quantifications were performed blinded to the injection groups. Glial representative images were acquired on an FV3000 confocal microscope (Olympus).
Super resolution microscopy and quantification of synaptic densities
Tissue sections prepared for super resolution imaging were mounted on charged slides as described and coverslipped with ProLong Glass Antifade mounting medium (P36980, Invitrogen) using 170 ± 5 µm No. 1.5H High Precision cover glasses. Bassoon- and PSD95-immunopositive puncta were captured using the Zeiss Elyra 7 super resolution microscope with Lattice SIM2. Images were acquired using a 63 × oil objective. 3.91 µm z-stacks were imaged at a step size of 0.126 µm, with laser power 0.9% and 90 ms exposure, and subsequently processed using the SIM2 ‘Low contrast’ reconstruction settings. The total numbers of Bassoon- and PSD95-puncta per z-stack were determined by thresholding using Imaris Software and normalized per mm3 of tissue.
Statistical analysis
Statistical analyses were performed using GraphPad Prism software. The normality of the distribution and homoscedasticity were checked prior to analysis and the corresponding parametric or non-parametric statistical tests performed. Paired tests were used for the comparison between SARK and HMW tau derived from the same AD cases. For in vivo experiments, statistical tests were followed by post hoc multiple comparisons between all three injection groups to account for both the effect of the injected tau seeds (HMW tau vs PBS, SARK tau vs PBS) and the effect of the nature of the tau seeds (HMW tau vs SARK tau). Data are represented as mean and standard error of mean (mean ± SEM). Outliers identified by GraphPad Prism software ‘Identify outlier’ plug-in (ROUT Q = 5%) were removed from the analysis.
Discussion
AD is a progressive neurodegenerative disease characterized by the presence of amyloid plaques and NFTs in the brain of cognitively impaired patients [
1]. NFTs are formed by the aggregation of the microtubule-associated tau protein and their presence has been historically associated with the progression of the disease [
2,
9,
19]. Tau protein is physiologically present in the brain of every individual. However, under pathological conditions, the tau protein undergoes various modifications leading to its accumulation and progressive oligomerization into mature aggregates [
38], suggesting that multiple tau species with various characteristics may co-exist in an AD brain. Here, we directly compared fibrillar SARK and oligomeric HMW tau derived from the same AD brain to determine their relative contribution to tau pathology progression while accounting for interindividual heterogeneity [
17]. We show that, despite having similar seeding activities in vitro and in vivo, only oligomeric HMW tau induces a peculiar rod-like microglial phenotype at the injection site, induces a stronger astrocytic response, has specific effects on tau subcellular localization and possible maturation, and propagates at least as strongly to the entorhinal cortex when injected into the hippocampus of male PS19 mice. Our data strengthen the idea of multiple bioactive tau species within each AD brain and position oligomeric HMW tau as having at least equal potency as SARK tau in terms of seeding and propagation to distally connected regions. If anything, HMW tau appears to generate a more pronounced neuroinflammatory response than fibrillar SARK tau. Since the biological potency of the preparations is also likely related to local concentrations, we further postulate that, in the intact brain, the freely soluble HMW species may also be more bioavailable than aggregated tau.
Recent SEC data showed that different tau species can co-exist in the brain ranging from high to low molecular weight species reflecting tau oligomers and tau monomers, respectively [
57], in addition to the well-described fibrillar forms that are the major constituent of NFTs. The fact that HMW tau oligomers are found in low quantities in non-AD brains [
57] could reflect either a physiological function for this tau species or reflect a transient state. By contrast, the presence of SARK tau fibrils seems restricted to NFT-bearing cases, suggesting that the presence of fibrillar tau in the brain is abnormal, as no SARK tau fibrils can be isolated from controls. Both SARK and HMW tau have been individually reported in abundance in the AD brain with detectable bioactivities [
17,
22,
56,
57]. Recently, tau filaments have been reported not only in sarkosyl-insoluble AD brain samples, but also in aqueous samples [
55] and it has also been suggested that short tau filaments are the most seed-competent form of tau [
28]. We used standard protocols established in the literature [
17,
22,
42,
57] to extract HMW oligomeric tau from PBS-soluble brain fractions, and SARK fibrillar tau from sarkosyl-insoluble brain fractions. These differences in solubility and proteinase K resistance (Fig.
1a-c) suggest that SARK and HMW tau are biochemically distinct tau species, consistent with mass spectrometry data [
60]. Moreover, the low abundance of fibrils in HMW compared to SARK preparations, as quantified by negative stain EM, provides morphological data consistent with the conclusion that the two preparations, defined by solubility characteristics, show overlap (as expected) but are biochemically distinct.
We also asked if the biochemical distinctions between the preparations translated into differences in bioactivity. SARK and HMW preparations show similar bioactivity in the standard HEK cell bioactivity assay reporting templated misfolding of a tau reporter. This is unlikely due to contamination of HMW preparations by fibrils, because when HMW tau is sonicated with 60 pulses, similarly to SARK tau, and filaments are no longer detected, the in vitro seeding activity remains. This result is consistent with the idea that the soluble non-fibrillar oligomeric species in the HMW sample is responsible for its in vitro bioactivity, and that both soluble and fibrillar forms of tau can support templated misfolding as measured by the bioassay. Moreover, while both SARK and HMW tau can support templated misfolding in vivo, their biological activity differs in potentially important ways—again evidence in favor of the idea that they are different tau species. Although it is possible that differences in extraction protocols in different laboratories could impact results, our data suggest that the observed bioactive effects, both in vitro and in vivo, result of the most representative tau species we observe in each sample, i.e., PHF-like tau fibrils and HMW tau oligomers for SARK and HMW tau, respectively. By isolating SARK fibrillar and HMW oligomeric tau from the same AD case, we confirm previous studies [
36,
37], showing that two biochemically distinct tau species co-exist in the AD brain.
The development of AD models has allowed the individual study of tau fibrils and tau oligomers, which resulted in the conclusion that not only fibrillar [
22,
25,
26,
44] but also oligomeric tau species can be bioactive [
7,
13,
35,
43,
45,
53,
62,
66], but no detailed, direct comparison of these two species across multiple cases has been carried out. Using the well-established FRET-based biosensor cell assay [
24], we confirm that both SARK tau fibrils and HMW tau oligomers are essentially equally bioactive in vitro, suggesting that both have equal ability to recruit the reporter construct, a P301S-mutated tau repeat domain. We next turned to a more complex biological system and took advantage of the commonly used P301S tau transgenic (PS19) mouse model to evaluate the biological activity of the different tau seeds in vivo. As expected [
8,
17], AD brain-derived SARK and HMW tau both increase tau pathology in the hippocampus of PS19 mice 3 months after injection. Consistent with the in vitro data, endogenous tau is similarly seeded by SARK fibrillar and HMW oligomeric tau as the number of tau-positive hippocampal neurons is comparable between the two injection groups. These data show again that SARK tau fibrils and HMW tau oligomer preparations, derived from a same brain, have similar seeding abilities, despite exhibiting different biochemical characteristics.
Interestingly, despite similar tau seeding activities between the tau seeds, we observe different tau accumulation patterns after injection into the hippocampus. HMW tau triggers tau pathology in neuronal somas, while SARK tau enhances tau accumulation in the dendritic processes of the
stratum oriens and
stratum radiatum. We obtain the same results after injecting SARK and HMW tau into the hippocampus of Tau22, mice which express a double-mutated G272V/P301S human tau, suggesting that the neuronal localization of pathological tau protein depends on the characteristics of the injected tau seeds, rather than the nature of the templated endogenous tau protein. These findings echo a recent publication reporting the differential distribution of seeded tau pathology after the injection of PS19 mouse-derived fibrillar and oligomeric tau into 3-month-old PS19 mice [
29]. Endogenous tau templated by either tau fibrils or oligomers thus seems to replicate the initial difference between fibrillar and oligomeric tau seeds. However, the mechanisms underlying tau recruitment to the dendritic compartments remain unclear [
27].
The hypothesis of prion-like cell-to-cell propagation of tau pathology has been reinforced by several studies in animal models [
15,
16]. The injection of AD-derived tau fibrils into the hippocampus of either tau transgenic or WT animals leads to the appearance of tau pathology in brain regions distal but anatomically connected to the injection site [
8,
22,
42]. It has also been shown that AD-derived tau oligomers can transmit from cell to cell in vitro [
57]. We compared the extent of tau pathology in two brain regions distal from the injection site. In this model, while the injection of both SARK tau fibrils and HMW tau oligomers led to similar levels of tau pathology at the injection site in the hippocampus and in the isocortex, and both propagated to peri-/entorhinal cortex, ThioS-positive mature tau aggregates were increased in the synaptically connected peri-/entorhinal cortex in the HMW tau-injected animals only. Similar observations have been made in WT mice, where tau pathology was confined to the injection site after the intrahippocampal injection of brain-derived tau fibrils, but the injection of tau oligomers from the same AD case led to the appearance of tau pathology in distally connected brain regions [
36]. This differential ability to propagate between SARK and HMW tau might result from the size of tau particles in each sample. Indeed, studies of the prion protein have shown that the most infectious and propagation-prone particles were about 300–600 kDa, similar size range to HMW tau, compared to larger fibrils [
52]. Post-translational modification differences between SARK and HMW tau as reported recently [
60] may also account for differential trafficking between these two tau species. Considering the several different pathways of pathological tau secretion and spreading [
10] as well as the involvement of neuronal activity in tau pathology progression [
12,
46,
63], the rate of progression of SARK and HMW tau could be influenced by multiple, yet unexplored, biological factors.
Besides amyloid plaques and NFTs, AD pathology is accompanied by neuronal and synaptic loss as well as neuroinflammation, including astrocytic and microglial activation [
50]. We evaluated changes in glial abundance and morphology in the brain of the injected animals using the commonly used markers GFAP for astrocytes and Iba1 for microglia. Compared to the PBS-injected PS19 mice, only the HMW oligomeric tau-injected animals displayed increased area covered by GFAP suggesting a differential astrocytic response depending on the nature of the injected tau seed. Recent analysis of the astrocytic signature in a P301S tau mouse model showed that reactive astrocytes can adopt multi-faceted changes to adapt to the local environment as shown by increased expression of genes involved in protein degradation for instance [
30]. Astrocytic functions involve synaptic pruning [
14] and neuronal circuit remodeling [
48] as well as neuronal tau uptake [
39,
41] making them prone to neurodegeneration and tau propagation. Curiously, we observe increased GFAP staining in the HMW tau-injected animals, which are the only ones showing tau propagation to the entorhinal cortex.
On the other hand, we did not find any group difference in Iba1 percent area at the injection site, despite them being different in the amount of tau pathology, suggesting that Iba1-related microglial response is not affected by the increase of tau-positive neurons in this model. The PS19 mouse model exhibits signs of neuroinflammation beginning at 3 months of age, before the appearance of tau aggregates [
66]. Therefore, the absence of a difference between the tau-injected and control animals at the time of killing (6 months of age) suggests that microglial activation might have plateaued when the first spontaneous or induced tau tangles appeared. These data are consistent with a previous study, where 6 months after the injection of AD brain homogenates into ALZ17 Tau transgenic mice, no difference in microglial activation was observed using the Iba1 microglial marker compared to controls [
15].
Surprisingly, when we looked closer at the morphology of Iba1-positive microglia, we observed the appearance of abundant rod-like microglia in the hippocampus of HMW tau-injected animals only. Rod microglia were first described a century ago by Nissl, yet their function and origin remain unknown. To this day, rod microglia are only characterized by their morphology presenting an elongated and narrow cell body and very few planal processes. These rod microglia are often described as following and enveloping neuronal processes, and can also assemble forming long train-like structures [
21]. Historically, rod microglia were described in the brain of patients suffering from an infectious disease like typhus or syphilis [
58]. More recently, rod microglia have been reported in the brain of elderly [
5], AD patients [
6], in cases of traumatic brain injury (TBI) [
61,
68], epilepsy [
64] and in hypoxic/ischemic conditions [
34]. Interestingly, these Iba1-positive rod microglia that we solely observe in the HMW tau-injected PS19 mice are also present in the gray matter of the AD cases from where the tau seeds were extracted, showing that the injection model recapitulates the human AD pathological environment and suggesting that in the human AD brain rod microglia might be somehow triggered by oligomeric forms of tau.
Very little is known about this microglial phenotype, therefore we explored the expression of Clec7a, one marker of disease-associated (DAM) microglia together with other markers [
31] at the crosstalk between infectious diseases and AD. Clec7a (or Dectin-1) is a β-glucan receptor expressed by myeloid cells with both exogenous microbial and endogenous ligands [
40]. Interestingly, Clec7a has been reported to be involved in the inflammatory response following not only AD, but also TBI and stroke [
65], all being pathological conditions associated with rod microglia. Triple staining for microglia (Iba1), pathological tau (AT100) and Clec7a in the different conditions revealed that Clec7a-positive Iba1-positive microglia are restricted to the HMW oligomeric tau-injected animals, and that these cells are not necessarily in the vicinity of tau-positive somas or processes. In the hippocampus, all Clec7a-positive microglia seem rod-like, but not all rod-like microglia are Clec7a-positive, suggesting an additional molecular level of diversity among morphologically similar microglia. In this model, the presence of rod microglia is restricted to the injection site, suggesting the involvement of the injected HMW oligomeric tau in the trigger of this peculiar microglial phenotype. In contrast, we observed Clec7a-positive microglia all along the propagation pathway of bioactive tau seeds, starting from the targeted CA1 pyramidal neurons to the entorhinal cortex. Clec7a-positive microglia were particularly abundant in the
stratum radiatum and the molecular layer of the hippocampus where CA1 pyramidal dendrites and axons are located, respectively, suggesting that Clec7a-positive microglia could be a readout for tau seed propagation.
In summary, we show that SARK fibrillar and HMW oligomeric tau samples derived from the same AD case induce similar tau-related phenotypes, yet trigger differential and specific cellular effects. Both tau fibrils and tau oligomers can seed endogenous tau, but patterns of neuronal tau accumulation differ, as do the properties of propagated species. Most importantly, we report a differential glial response with the appearance of a peculiar and poorly characterized rod-like microglial phenotype in the oligomeric tau-injected animals only. Therefore, the data strongly suggest that various tau seeds co-exist in the AD brain and that these tau seeds have unique intrinsic properties that are, in the present study, reflected at the biological level. These observations confirm the intraindividual heterogeneity of tau species in AD, opening doors to novel and better targeted anti-tau therapeutic strategies.